The online home for the primary care professionals managing patients with cardiovascular disease, diabetes and related diseases.

PCSK9 inhibition in lipid management

PCSK9 inhibition in lipid management

Publication date: Monday, 12 September 2016
Contributor(s): Anthony S Wierzbicki

Two injectable antibody-based therapies inhibiting the activity of PCSK9 - alirocumab and evolucumab - have recently been licensed. This paper reviews the current status of lipid management, the actions of PCSK9, and the clinical trial results achieved with PCSK9 inhibitors in early studies.

Topics covered:
Category: Editorial
Edition: Volume 1 Number 4 PCCJ Online 2016
Contributor(s): Anthony S Wierzbicki

Article search and filter